Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-140-3p agomir
- Development stage
- Preclinical
- Lead developer
- MedChemExpress
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Subcutaneous
01
Overview
miR-140-3p agomir is a chemically-modified, double-stranded microRNA (miRNA) mimic designed to emulate the endogenous miR-140-3p. It features specific modifications to enhance stability and cellular uptake, including phosphorothioate linkages at the 5' and 3' ends, a 3' cholesterol group, and full-length 2'-methoxy modifications. Biologically, it acts by targeting and downregulating specific mRNAs, notably SUZ12 and components of the MAP2K6/p38 signaling pathway. Research has explored its potential in modulating disease processes in acute myeloid leukemia (AML), pulmonary arterial hypertension (PAH), and various cardiovascular conditions. It is primarily utilized as a research tool to study miRNA function in vivo and in vitro.
- Other names
- microRNA-140-3p agomirmicroRNA140-3p agomirmicroRNA 140-3p agomirhsa-miR-140-3p agomirhsa-miR140-3p agomirhsa-miR 140-3p agomir
02
Targets
SUZ12 (Suppressor of zeste 12 protein homolog)MAP2K6 (MEK6)
Beyond the preview
Go deeper on miR-140-3p agomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-140-3p agomir.